This Book >>

  • 326pp. Published June 2017
  • Scientific Research Publishing, Inc.,USA.
  • Category: Biomedical & Life Sciences
  • ISBN: 978-1-61896-324-6
  • (Hardcover) USD 109.00
  • ISBN: 978-1-61896-323-9
  • (Paperback) USD 89.00
Authors/Editors Price: 40% off
Buy at: bookorder@scirp.org

Connect with SCIRP >>

Home > Books > Advances in Hematopoietic Stem Cell Tran...
Advances in Hematopoietic Stem Cell Transplantation
  • Description
  • Author(s) Information

Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood. It may be autologous (the patient’s own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin). It is a medical procedure in the field of hematology, most often performed for patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia. In these cases, the recipient’s immune system is usually destroyed with radiation or chemotherapy before the transplantation. Infection and graft-versus-host disease are major complications of allogeneic HSCT. Hematopoietic stem cell transplantation remains a dangerous procedure with many possible complications; it is reserved for patients with life-threatening diseases. As survival following the procedure has increased, its use has expanded beyond cancer, such as autoimmune diseases.


In the present book, fifteen typical literatures about hematopoietic stem cell transplantation published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on medical science, transplantation medicine, hematology, stem cells, epidemiology, ect. We hope this book can demonstrate advances in hematopoietic stem cell transplantation as well as give references to the researchers, students and other related people.

Components of the Book:
  • Chapter 1
    The Clinical Application of Mesenchymal Stromal Cells in Hematopoietic Stem Cell Transplantation
  • Chapter 2
    Non-Traditional CD4+CD25−CD69+ Regulatory T Cells Are Correlated to Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
  • Chapter 3
    The Role of Telomeres and Telomerase in Hematologic Malignancies and Hematopoietic Stem Cell Transplantation
  • Chapter 4
    Utilization of TREC and KREC Quantification for the Monitoring Of Early T- And B-Cell Neogenesis in Adult Patients after Allogeneic Hematopoietic Stem Cell Transplantation
  • Chapter 5
    Hematopoietic Stem Cell Transplantation (HSCT) as an Example of Personalized Approach in the Management of Individual Disease
  • Chapter 6
    AFM Detection of Biophysical Characteristics of Specific Regulatory T Cells after Allogeneic Hematopoietic Stem Cell Transplantation
  • Chapter 7
    Infused Autograft Lymphocyte-To-Monocyte Ratio and Survival in T-Cell Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation
  • Chapter 8
    Kinetics of Langerhans Cell Chimerism in the Skin of Dogs Following 2 Gy TBI Allogeneic Hematopoietic Stem Cell Transplantation
  • Chapter 9
    Donor Vδ1+ γδ T Cells Expand after Allogeneic Hematopoietic Stem Cell Transplantation and Show Reactivity against CMV-Infected Cells but Not against Progressing B-CLL
  • Chapter 10
    Epstein–Barr Virus-Associated Posttransplant Lymphoproliferative Disorder Involving the Central Nervous System Following Autologous Hematopoietic Stem Cell Transplantation for Neuroblastoma
  • Chapter 11
    L-Asparaginase-Based Regimens Followed by Allogeneic Hematopoietic Stem Cell Transplantation Improve Outcomes in Aggressive Natural Killer Cell Leukemia
  • Chapter 12
    Pediatric Donor Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation in AML Patient from Related Donor
  • Chapter 13
    Plerixafor (A CXCR4 Antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Hematopoietic Recovery
  • Chapter 14
    Changes of Serum Aspergillus Galactomannan during Hematopoietic Stem Cell Transplantation in Children with Prior Invasive Aspergillosis
  • Chapter 15
    Novel Treatment of Severe Combined Immunodeficiency Utilizing Ex-Vivo T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation and CD45RA+ Depleted Donor Lymphocyte Infusions
Readership: Students, academics, teachers and other people attending or interested in Hematopoietic Stem Cell Transplantation.
comments powered by Disqus